Ligand Pharmaceuticals LGND Weighted Average Exercise Price of Outstanding Options
Weighted Average Exercise Price of Outstanding Options at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's weighted average exercise price of outstanding options.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's weighted average exercise price of outstanding options?
- Ligand Pharmaceuticals (LGND) reported weighted average exercise price of outstanding options of $101.43 in Q1 2026.
- How has Ligand Pharmaceuticals's weighted average exercise price of outstanding options changed year-over-year?
- Ligand Pharmaceuticals's weighted average exercise price of outstanding options increased by 24.5% year-over-year, from $81.45 to $101.43.
- What is the long-term trend for Ligand Pharmaceuticals's weighted average exercise price of outstanding options?
- Over 3 years (2022 to 2025), Ligand Pharmaceuticals's weighted average exercise price of outstanding options has grown at a 11.3% compound annual growth rate (CAGR), from $61.31 to $84.48.
- What does weighted average exercise price of outstanding options mean?
- This metric calculates the average price at which holders of outstanding stock options can purchase company shares. It provides context on the 'in-the-money' status of employee compensation packages. When compared to the current market price, it helps assess the alignment between employee incentives and shareholder value.